Date: 2012-05-17
Type of information: Licensing agreement
Compound: MET4 antibody
Company: Dako (Denmark) Van Andel Research Institute (USA)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism:
Disease:
Details: * On May 17, 2012, Van Andel Research Institute (VARI) and Dako, the Danish-based, worldwide supplier of cancer diagnostic tools today announce an agreement to license, manufacture and distribute cancer diagnostics utilizing the MET4 antibody. This antibody can be used to detect the human MET oncogene in human tumors. Diagnostic tools with the MET4 Antibody will be developed and manufactured by Dako for clinically relevant diagnostic indications and commercialized worldwide. Dako also holds the right to develop MET4 companion diagnostic assays (pharmDxTM assays) in collaboration with pharmaceutical companies to identify cancer patients who may benefit from MET-targeted therapies.
Financial terms:
Latest news:
